Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Current Topics in Medicinal Chemistry
|
March 23, 2004
Automation in medicinal chemistry
John C Reader
Organic Letters
|
November 18, 2005
Deconjugation of dehydroamino acids: stereoselective synthesis of racemic (E)-vinylglycines
Paul A Alexander, Stephen P Marsden, Dulce M Muñoz Subtil, et al.
Journal of Combinatorial Chemistry
|
February 8, 2002
Design, synthesis, and biological evaluation of a library of 1-(2-thiazolyl)-5-(trifluoromethyl)pyrazole-4-carboxamides
Bridget A Donohue, Enrique L Michelotti, John C Reader, et al.
Combinatorial Chemistry & High Throughput Screening
|
August 24, 2006
Exploring structure-activity relationships of tricyclic farnesyltransferase inhibitors using ECLiPS libraries
Laura L Rokosz, Chia-Yu Huang, John C Reader, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 6, 2005
Surfing the piperazine core of tricyclic farnesyltransferase inhibitors
Laura L Rokosz, Chia-Yu Huang, John C Reader, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 18, 2005
Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc
Chia-Yu Huang, Tara M Stauffer, Corey L Strickland, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
Thomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Michael I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Current Topics in Medicinal Chemistry
|
March 23, 2004
Automation in medicinal chemistry
John C Reader
Organic Letters
|
November 18, 2005
Deconjugation of dehydroamino acids: stereoselective synthesis of racemic (E)-vinylglycines
Paul A Alexander, Stephen P Marsden, Dulce M Muñoz Subtil, et al.
Journal of Combinatorial Chemistry
|
February 8, 2002
Design, synthesis, and biological evaluation of a library of 1-(2-thiazolyl)-5-(trifluoromethyl)pyrazole-4-carboxamides
Bridget A Donohue, Enrique L Michelotti, John C Reader, et al.
Combinatorial Chemistry & High Throughput Screening
|
August 24, 2006
Exploring structure-activity relationships of tricyclic farnesyltransferase inhibitors using ECLiPS libraries
Laura L Rokosz, Chia-Yu Huang, John C Reader, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 6, 2005
Surfing the piperazine core of tricyclic farnesyltransferase inhibitors
Laura L Rokosz, Chia-Yu Huang, John C Reader, et al.
Bioorganic & Medicinal Chemistry Letters
|
November 18, 2005
Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc
Chia-Yu Huang, Tara M Stauffer, Corey L Strickland, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 22, 2010
Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases
Thomas P Matthews, Tatiana McHardy, Suki Klair, et al.
Molecular Cancer Therapeutics
|
January 8, 2010
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106
Michael I Walton, Paul D Eve, Angela Hayes, et al.
Journal of Medicinal Chemistry
|
October 23, 2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Page
of 2